Literature DB >> 1531444

Extrapyramidal reaction to ondansetron.

J R Halperin1, B Murphy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1531444     DOI： 10.1002/cncr.2820690533

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  7 in total

1.  Improvement of hemichorea with ondansetron.

Authors:  O O Erdinç; G Ozdemir; S Uysal; D Gücüyener; S Torun
Journal:  Postgrad Med J       Date:  1997-02       Impact factor: 2.401

Review 2.  Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.

Authors:  G L Plosker; R J Milne
Journal:  Pharmacoeconomics       Date:  1992-10       Impact factor: 4.981

Review 3.  Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.

Authors:  B K Young; R Camicioli; L Ganzini
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

4.  Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo.

Authors:  R M Eglen; C H Lee; W L Smith; L G Johnson; R Clark; R L Whiting; S S Hegde
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

Review 5.  Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.

Authors:  Anthony Markham; Eugene M Sorkin
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 6.  Reducing chemotherapy-induced nausea and vomiting. Current perspectives and future possibilities.

Authors:  A Del Favero; F Roila; M Tonato
Journal:  Drug Saf       Date:  1993-12       Impact factor: 5.606

Review 7.  Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy.

Authors:  Y E Yarker; D McTavish
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.